Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bausch & Lomb and CrystalGenomics have signed a joint research and development agreement to study potential new treatments for inflammatory ophthalmic diseases.
Subscribe to our email newsletter
CrystalGenomics will provide new pharmaceutical candidate compounds while Bausch & Lomb will develop product formulations, conduct pre-clinical and clinical studies, and bring the products to market.
Praveen Tyle, chief scientific officer of Bausch & Lomb, said: “We believe this collaboration has the potential to extend our leadership in anti-inflammatory ophthalmic pharmaceuticals, especially with CrystalGenomics’s unique 3D structure-based optimization technology for compound discovery.”